BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Clinical strategy at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
39 organizations at BIO-Europe 2026 present work in clinical strategy: 24 service providers, 12 drug developers, 2 investors and 1 academic, government or non-profit body. Between them they bring 55 presentations to the program. Most represented: Bayer (6 on the program), Biogen (4 on the program), Miltenyi Biomedicine (3 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–14 of 39 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Bayer Leverkusen, Germany | ◆Platinum Sponsor |
Life sciences company with pharmaceuticals, consumer health and crop science divisions. | Talk Tue Nov 10 09:00–09:30 An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. Panel Tue Nov 10 16:30–16:55 The Role of Innovation in Biopharma Growth How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 11:00–12:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. |
Biogen Cambridge, Massachusetts | ◆Platinum Sponsor |
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. | Talk Mon Nov 9 09:00–10:00 Build, Buy, or Partner? Choosing Your Market Entry Strategy How drug companies choose between licensing a new product to a regional partner, selling it themselves, or both, with lessons from each path. Business of Biotech Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 15:00–15:45 Mastering the Shifting Regulatory Landscape: Leveraging the Biotech Act for Innovation and Global Success How the EU Biotech Act aims to restore Europe's edge through faster trial approvals, quicker rare disease access and proportionate oversight of advanced therapies. |
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change. |
Regulatory consultancy advising drug developers on regulatory and commercialization pathways, including gene therapy applications. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy Panel Tue Nov 10 13:00–13:55 Unlocking APACs Clinical Trials Potential: Navigating Regulatory Pathways, Bridging Strategies and Market Access Across the Region How to run clinical trials and win approval in Japan, Korea, Taiwan and Southeast Asia, and when studies in local patients pay off. |
Parexel Durham, NC | ◆Platinum Sponsor |
Clinical research organization providing clinical development, regulatory consulting and market access services to biopharmaceutical companies. | Panel Tue Nov 10 14:00–14:25 Navigating the Evolving Regulatory Landscape: Strategies for Clinical Success in an Era of Transformation How rare disease drugs can win approval with few patients, how FDA leadership changes shift priorities, and how real-world data can strengthen applications. Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. |
A Atrogi Stockholm, Sweden | |
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle. | Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
Australian not-for-profit organization providing human research ethics committee review for clinical trials and other health research. | Panel Wed Nov 11 09:55–10:25 What Starts Down Under Doesn’t Stay Down Under: Australian Clinical Data as a Global Launchpad How companies use clinical data gathered in Australia to move into multinational trials, raise investment and launch products worldwide. |
Scientia Clinical Research Sydney, Australia | |
Not-for-profit first-in-human Phase 1 clinical trial unit in the Randwick health precinct, also running later-phase oncology and haematology trials. | Panel Tue Nov 10 14:30–15:00 Accelerating First-in-Human: Why Australia is the Fast Track to the Clinic Why Australia suits a drug's first trials in people, with supportive rules, engaged doctors and data that European and US regulators accept. |
Develops oral small-molecule allosteric inhibitors for chronic inflammation, fibrosis and cancer, led by an oral inhibitor of IL-1β production. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for Rare Disease Therapeutics How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed. Panel Wed Nov 11 09:00–09:25 Learning from Failures and Successes in Clinical Trials What failed and successful clinical trials teach about designing and running better trials, using real examples. |
CT Cellula Therapeutics Epalinges, Switzerland | |
Swiss cell therapy biotech spun out of the University of Geneva. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for Rare Disease Therapeutics How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed. Panel Wed Nov 11 11:00–11:45 Capital with a Mission: Investing Beyond Traditional Venture Models How mission-driven and foundation investors fund neglected diseases such as glioblastoma and neuroblastoma that venture capital passes over, focusing on Switzerland. |
Consultancy advising pharma, medtech and digital health companies on China-Europe policy, regulation, market access and expansion. | Talk Tue Nov 10 09:30–09:45 Before the Deal: What Western Buyers Must Resolve About China-Origin Evidence and Policy Risk What Western buyers should check before buying rights to a China-developed drug, from whether its trial data satisfy European regulators to political risk. Panel Tue Nov 10 09:45–10:45 China’s Clinical Revolution: From Regional Player to Global Innovation Engine Why global drug companies license more drugs from Chinese biotechs, and how China's fast trials and changing rules can speed worldwide development. |
◆Platinum Sponsor | |
AI company offering AI-powered clinical development services and software, from protocol design and data management to regulatory documents. | Talk Mon Nov 9 09:00–10:00 Doctor-to-Doctor: A PI-Led Pathway into Japan Using AI, DCT, and Registration-Directed Investigator-Initiated Trials to Reach Japanese Patients Faster How trials led by the right Japanese doctor, rather than a contract research company, can take a drug toward approval in Japan. Clinical StrategyRegulatory Strategy |
◇Silver Sponsor | |
Clinical trial planning software and data covering patient, country and site feasibility, for pharma and biotech companies and contract research organizations. | Panel Tue Nov 10 15:00–15:25 Expanding Global Clinical Trials: Opportunities and Challenges in Emerging Markets How to expand clinical trials into emerging markets and underserved groups, from picking contract research companies and sites to building local partnerships. |
AB Agilex Biolabs Adelaide, Australia | |
Australian bioanalytical laboratory providing regulated bioanalysis, toxicology and immunology testing for clinical trials. | Panel Tue Nov 10 14:30–15:00 Accelerating First-in-Human: Why Australia is the Fast Track to the Clinic Why Australia suits a drug's first trials in people, with supportive rules, engaged doctors and data that European and US regulators accept. |
Find buyers in clinical strategy
Tell us what you sell and we’ll find the people at organizations working on clinical strategy most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction